Bimatoprost as a Treatment for Graves' Orbitopathy

Early Phase 1RecruitingNCT03708627

Johns Hopkins University3 enrolled

Overview

Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Graves Ophthalmopathy

Interventions

Bimatoprost OphthalmicDRUG

Bimatoprost, aka Lumigan, one drop in one eye nightly

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Graves' Ophthalmopathy with Exophthalmos/Proptosis - Exclusion Criteria: Active Graves Disease, Currently pregnant, Taking Steroids \-

Locations (1)

University of Washington

Seattle, Washington, United States

RECRUITING

Outcomes

Primary Outcomes

Reduction in periorbital fat causing improvement in proptosis

Time frame: 1 year

Central Contacts

Emily Li, MD

CONTACT

410-955-1112 eli20@jhmi.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.